UPCOMING SESSIONS in ET
Tue, Jun 30, 2026
5:00 – 6:00 AM Bangkok
The Care Partner Conversation: Open communication and boundaries Samantha De Santiago Click To Register
UPCOMING SESSIONS in ET
Tue, Jun 30, 2026 · 5:00 – 6:00 AM Bangkok
The Care Partner Conversation: Open communication and boundaries
Samantha De Santiago
Click To Register
View all sessions

Abstract & Posters

Jun 18, 2018
Features of Atrial Fibrillation in Wild-Type Transthyretin Cardiac Amyloidosis: A Systematic Review and Clinical Experience
Aims: Wild-type transthyretin (ATTRwt) cardiac amyloidosis has emerged as an important cause of heart failure in the elderly. Atrial fibrillation (AF) commonly…
Read more
Jun 03, 2018
Subcutaneous Daratumumab (DARA SC) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Patients (Pts) With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Safety Run-in Results of Andromeda
Background: Systemic AL amyloidosis is characterized by disposition of insoluble amyloid fibrils into tissues and organs via clonal expansion of CD38+ plasma cells…
Read more
Mar 20, 2017
Implanted Cardiac Defibrillator and Pacemaker Lead Function in Patient With Cardiac Amyloidosis
Introduction: Cardiac amyloidosis (CA) results from myocardial infiltration of amyloid proteins that leads to restrictive cardiomyopathy, heart failure, and…
Read more
The Patient Voice: Development and Results of a Pilot Patient Experience Data Survey
Background Amyloidosis is a rare, systemic disease that is characterized by a variable pattern of nonspecific symptoms and affected organs. These characteristics…
Read more
Real-World Patient, Advocate, and Caregiver Perspectives on Amyloidosis: Awareness, Knowledge Gaps, and Psychosocial Impact
Background All types of amyloidosis are rare, progressive, and potentially fatal disorders that are difficult to diagnose and treat. Correct diagnosis of…
Read more
Daratumumab-Based Therapies in Patients With AL Amyloidosis
Background: Treatment options for patients (pts) with relapsed/refractory (RR) AL amyloidosis are limited. Daratumumab (dara) has been approved as monotherapy (DMT…
Read more
Subscribe to